Report: Extended-release Drugs Could be Costing Billions
March 2, 2020
A recent study published in JAMA Network Open suggests the U.S. health care system could save billions if doctors prescribed short-acting drugs instead of extended-release drugs, Reuters reports.
The study analyzed Medicare and Medicaid spending data between 2012-2017.
“It’s not a huge difference in terms of patient convenience, but the cost difference is remarkable,” University of Texas Southwestern Medical Center’s Dr. Ambarish Pandey, coauthor, said.
To read the full report on Reuters, click here.
